Patents Assigned to ABREXA PHARMACEUTICALS, INC.
  • Compositions and methods for prevention and treatment of coronavirus and related disorders
    Patent number: 11938104
    Abstract: Presented herein are compositions and methods for preventing, reducing, delaying and treating a coronavirus infection and related disorders such as respiratory distress, disseminated intravascular coagulation, and central nervous system pathologies caused by coronavirus infection.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: March 26, 2024
    Assignee: ABREXA PHARMACEUTICALS, INC.
    Inventors: Jesus E. Villafranca, Charles Richard Kissinger
  • 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene] method of making the same
    Patent number: 11584711
    Abstract: Crystalline polymorph forms of neurotrophic agent 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide (J147), and process for producing the crystalline polymorphic form are provided.
    Type: Grant
    Filed: January 17, 2021
    Date of Patent: February 21, 2023
    Assignee: ABREXA PHARMACEUTICALS, INC.
    Inventors: Michael O'Neill, Barbara Kidon, William A. Janz, Hongqiao Wu
  • 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene] hydrazide polymorphs and method of making the same
    Patent number: 10968167
    Abstract: Crystalline polymorph forms of neurotrophic agent 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide (J147), and process for producing the crystalline polymorphic form are provided.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: April 6, 2021
    Assignee: ABREXA PHARMACEUTICALS, INC.
    Inventors: Michael O'Neill, Barbara Kidon, William A. Janz, Hongqiao Wu